Lung Cancer: MK7684A-006

Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC

For more information please visit: https://classic.clinicaltrials.gov/ct2/show/NCT05298423?term=MK7684A-006&draw=1&rank=1